Mersana Therapeutics, Inc.

NasdaqGS MRSN

Mersana Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -79.45 M

Mersana Therapeutics, Inc. Operating Income is USD -79.45 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 59.72% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Mersana Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -197.25 M, a 4.21% change year over year.
Mersana Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -205.93 M, a -37.66% change year over year.
Mersana Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -149.59 M, a -96.96% change year over year.
Mersana Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -75.95 M, a -108.75% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGS: MRSN

Mersana Therapeutics, Inc.

CEO	Dr. Martin H. Huber M.D.
IPO Date	June 28, 2017
Location	United States
Headquarters	840 Memorial Drive
Employees	123
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years